GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS
August 31 2023 - 8:30AM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical device company focused on glucose monitoring technologies
for people with diabetes and prediabetes, announced today that it
has appointed Erin Carter to its Board of Directors and as Chair of
its Audit Committee, effective immediately.
Ms. Carter brings 30 years of executive level
finance experience in the medical device industry. From 2012 until
March of 2023, she held various senior roles with Medtronic, most
recently serving as Chief Financial Officer and Vice President of
Finance for their $9B Neuroscience division. In addition, during
her tenure at Medtronic she grew the Gastrointestinal Solutions
division from early tech start-up acquisition of $36M to revenue of
$450M in 5 years through organic growth and multiple acquisitions.
Prior to Medtronic, Ms. Carter served as Director of Finance at
Boston Scientific and as VP of Accounting and Reporting at
UnitedHealth Group. Prior to that, she served as Assistant
Controller for Arterial Vascular Engineering, where she was
instrumental in guiding the rapid growth of the company from 200
employees to over 4,000 in under five years. During this time, she
managed the integration of two acquisitions and subsequently the
company’s sale to Medtronic.
Ms. Carter holds a B.S. in Business
Administration from California Polytech State University and is a
Certified Public Accountant (inactive) in the State of
California.
“We are delighted to have Erin join our Board of
Directors,” said Paul Goode, CEO of Glucotrack. “She brings a
wealth of financial knowledge and expertise in working with young
companies and guiding them through strategic growth and expansion.
She will be a tremendous asset as we look ahead to growing the
organization and moving into the commercialization phase.”
“I am excited to join the Glucotrack board at
such a pivotal time in the Company’s evolution,” said Ms. Carter.
“I look forward to working with the Company’s leadership team to
advance its mission of developing and commercializing innovative
technologies to improve the lives of people with diabetes and to
build long-term value for shareholders."
About Glucotrack,
Inc.
Glucotrack, Inc. (NASDAQ: GCTK), (formerly known
as Integrity Applications, Inc.) is focused on the design,
development, and commercialization of novel technologies for people
with diabetes and prediabetes. The Company’s initial product,
Glucotrack®, is a proprietary non-invasive glucose monitoring
device designed to obtain glucose level measurements without the
pain, incremental cost, difficulty, or discomfort of conventional
invasive finger stick devices. For more information, please visit
and http://www.glucotrack.com.
Investor Contact: investors@glucotrack.com
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “expect”, “plan” and “will” are intended
to identify forward-looking statements. Readers are cautioned that
certain important factors may affect Glucotrack’s actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect Glucotrack’s results include, but are not
limited to, the ability of GlucoTrack to raise additional capital
to finance its operations (whether through public or private equity
offerings, debt financings, strategic collaborations or otherwise);
risks relating to the receipt (and timing) of regulatory approvals
(including FDA approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to its
current and future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2022 as filed with the SEC on March
31, 2023.
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From Apr 2024 to May 2024
GlucoTrack (NASDAQ:GCTK)
Historical Stock Chart
From May 2023 to May 2024